4.8 • 7.2K Ratings
🗓️ 7 June 2024
⏱️ 71 minutes
🧾️ Download transcript
Hey its Chalene Johnson, and today I'm chatting with Dr. Tyna Moore about the unconventional uses of semaglutide aka GLP 1 Agonists, Ozempic, Wegovy, Mounjaro, and Tirzepatide for treating cognitive decline, arthritis, brain fog, hormonal weight loss and more. Learn about weight loss peptides, low dosing and microdosing, minimizing side effects, and the importance of preserving muscle while using this game-changing drug. Don't miss out on this eye-opening discussion!
Watch this episode on YouTube on SUNDAY!
Learn More About Dr. Tyna
Related Episodes:
Join the all-new Phase It!! A Personalized Plan to Fit Your Life
👉Go to https://phaseitup.com
Join for FREE the 14-Day Energy Boost Blueprint!! 👉 http://myselfagain.com
Join me on Patreon http://chalene.com/more To listen to the Rachel and Dave Hollis Series!
Try now risk-free for 60 nights, at blissy.com/CHALENE and get an additional 30% off. That’s and use code CHALENE to get an additional 30% off! Your skin and hair will thank you!
To get the exclusive offer for my listeners go to Bioptimizers.com/chalene and enter code CHALENE to get 10% off any order!
We would love to hear from you! Leave your questions or messages for Chalene RIGHT HERE
To advertise on our podcast, please reach out to [email protected] and mention The Chalene Show
Join our awesome PodSquad on Facebook here!
Sign Up For MY WEEKLY NEWSLETTER
Links You May Want to Check out:
Connect with me on your fav social platform:
Click on a timestamp to play from that location
0:00.0 | Today's episode requires that you have an open mind because we're going to talk about some very nuanced approaches |
0:06.3 | some unconventional ways that experts like my guest Dr. Tina Moore are using |
0:10.9 | Somagletide to treat things like cognitive decline, arthritis, addiction, brain fog, |
0:17.0 | prevention of dementia, and midlife weight loss. |
0:21.0 | So if you've been kind of sitting on the fence or curious about how these |
0:24.6 | drugs seem to be so popular and why everyone's talking about them yet at the same time |
0:29.8 | you're terrified about all of the side effects you've been hearing about, today's |
0:33.6 | conversation is going to open your mind. We are going to talk about micro dosing, the |
0:38.6 | very lowest dose of some of these drugs in a way that's super affordable as little as $30 a month and not necessarily |
0:47.4 | for weight loss although it can be used for weight loss but my guest today is a very outspoken |
0:52.4 | advocate not just for the use of these drugs but for the proper use of these drugs and in fact she's probably one of the loudest |
1:00.5 | voices on the internet that I can think of who's saying that most doctors are |
1:04.5 | over prescribing these drugs. They're giving people too high of a dosage and that is |
1:09.2 | why we're seeing such negative side effects in some parts of the population but we're going to |
1:13.4 | break it all down today so if you've been wondering about the side effects if you've |
1:16.9 | been wondering if in fact you might be a candidate and how people are being able |
1:22.2 | to afford these drugs and can you get them from a compound |
1:26.0 | pharmacy all of those questions and more will be answered here today on the |
1:30.5 | Schlinge show. Dr. Tina Moore, my guest is a licensed naturopath physician. |
1:36.9 | She has spent several decades studying longevity and regenerative medicine. |
1:41.2 | She's an expert in metabolic and regenerative health and she's become one of the |
1:45.2 | most well-known advocates for the unconventional use of Ozempeck. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Chalene Johnson, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Chalene Johnson and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.